Prevalence and Predictors of Concomitant Bacterial Infections in Patients With Respiratory Viruses in Ontario: A Cohort Study

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2024 Dec 18

PMID 39691293

Authors

Yue Wang

Sarah Swayze

Kevin A Brown

Derek R MacFadden

Samantha M Lee

Kevin L Schwartz

Nick Daneman

Bradley J Langford

Affiliations

Soon will be listed here.

Abstract

Background: To investigate the prevalence of concomitant bacterial infection across common viral infections.

Methods: This population-based cohort study included patients infected with influenza A and B (FLUA, FLUB) and respiratory syncytial virus (RSV) in Ontario between 2017 and 2019 and patients with SARS-CoV-2 between 2020 and 2021. Specific bacteria present in concomitant infections were identified. Concomitant infections were further classified into different categories (eg, coinfection -2 to +2 days from viral infection and secondary infection >2 days after viral infection). We used logistic regression models to estimate the odds of bacterial infections for FLUA, FLUB, and RSV relative to SARS-CoV-2 while adjusting for confounders.

Results: A total of 4230 (0.5%, 885 004) viral cases had concomitant bacterial infections, encompassing 422 of FLUB (4.7%, 8891), 861 of FLUA (3.9%, 22 313), 428 of RSV (3.4%, 12 774), and 2519 of COVID-19 (0.3%, 841 026). The most prevalent species causing concomitant bacterial infection were , , and . When compared with SARS-CoV-2, the adjusted odds ratio for bacterial infection was 1.69 (95% CI, 1.48-1.93) for FLUA, 2.30 (95% CI, 1.97-2.69) for FLUB, and 1.56 (95% CI, 1.33-1.82) for RSV. The adjusted odds of coinfection in patients with SARS-CoV-2 were lower but higher for secondary infection as compared with the other viruses.

Conclusions: A higher prevalence and risk of concomitant bacterial infection were found in FLUA, FLUB, and RSV as compared with SARS-CoV-2, although this is largely driven by coinfections. Ongoing surveillance efforts are needed to compare the risk of concomitant infections during periods when these viruses are cocirculating.

References

Oliva J, Terrier O . Viral and Bacterial Co-Infections in the Lungs: Dangerous Liaisons. Viruses. 2021; 13(9). PMC: 8472850. DOI: 10.3390/v13091725. View

Langford B, So M, Raybardhan S, Leung V, Soucy J, Westwood D . Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021; 27(4):520-531. PMC: 7785281. DOI: 10.1016/j.cmi.2020.12.018. View

Murray H, Muleme M, Cooper D, McNamara B, Hussain M, Bartolo C . Prevalence, risk factors, and outcomes of secondary infections among hospitalized patients with COVID-19 or post-COVID-19 conditions in Victoria, 2020-2023. Int J Infect Dis. 2024; 145:107078. DOI: 10.1016/j.ijid.2024.107078. View

Langford B, So M, Simeonova M, Leung V, Lo J, Kan T . Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis. Lancet Microbe. 2023; 4(3):e179-e191. PMC: 9889096. DOI: 10.1016/S2666-5247(22)00355-X. View

Lansbury L, Lim B, Baskaran V, Lim W . Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020; 81(2):266-275. PMC: 7255350. DOI: 10.1016/j.jinf.2020.05.046. View

Weiser J, Ferreira D, Paton J . Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. 2018; 16(6):355-367. PMC: 5949087. DOI: 10.1038/s41579-018-0001-8. View

Lin H, Liu Y, Hsing T, Chen L, Liu Y, Yen T . RSV pneumonia with or without bacterial co-infection among healthy children. J Formos Med Assoc. 2021; 121(3):687-693. DOI: 10.1016/j.jfma.2021.08.012. View

Kumar A, Zarychanski R, Pinto R, Cook D, Marshall J, Lacroix J . Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA. 2009; 302(17):1872-9. DOI: 10.1001/jama.2009.1496. View

Zamora-Cintas M, Lopez D, Blanco A, Rodriguez T, Segarra J, Novales J . Coinfections among hospitalized patients with covid-19 in the first pandemic wave. Diagn Microbiol Infect Dis. 2021; 101(3):115416. PMC: 8102383. DOI: 10.1016/j.diagmicrobio.2021.115416. View

10.

Langford B, So M, Raybardhan S, Leung V, Westwood D, MacFadden D . Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020; 26(12):1622-1629. PMC: 7832079. DOI: 10.1016/j.cmi.2020.07.016. View

11.

HERS J, Masurel N, Mulder J . Bacteriology and histopathology of the respiratory tract and lungs in fatal Asian influenza. Lancet. 1958; 2(7057):1141-3. DOI: 10.1016/s0140-6736(58)92404-8. View

12.

Patton M, Orihuela C, Harrod K, Bhuiyan M, Dominic P, Kevil C . COVID-19 bacteremic co-infection is a major risk factor for mortality, ICU admission, and mechanical ventilation. Crit Care. 2023; 27(1):34. PMC: 9868503. DOI: 10.1186/s13054-023-04312-0. View

13.

Meskill S, OBryant S . Respiratory Virus Co-infection in Acute Respiratory Infections in Children. Curr Infect Dis Rep. 2020; 22(1):3. PMC: 7223550. DOI: 10.1007/s11908-020-0711-8. View

14.

Layton A, Sadria M . Understanding the dynamics of SARS-CoV-2 variants of concern in Ontario, Canada: a modeling study. Sci Rep. 2022; 12(1):2114. PMC: 8826311. DOI: 10.1038/s41598-022-06159-x. View

15.

Morens D, Taubenberger J, Fauci A . Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008; 198(7):962-70. PMC: 2599911. DOI: 10.1086/591708. View

16.

Martin-Loeches I, Schultz M, Vincent J, Alvarez-Lerma F, Bos L, Sole-Violan J . Increased incidence of co-infection in critically ill patients with influenza. Intensive Care Med. 2016; 43(1):48-58. DOI: 10.1007/s00134-016-4578-y. View

17.

Gill J, Sheng Z, Ely S, Guinee D, Beasley M, Suh J . Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med. 2010; 134(2):235-43. PMC: 2819217. DOI: 10.5858/134.2.235. View

18.

Joseph C, Togawa Y, Shindo N . Bacterial and viral infections associated with influenza. Influenza Other Respir Viruses. 2013; 7 Suppl 2:105-113. PMC: 5909385. DOI: 10.1111/irv.12089. View

19.

Murthy S, Archambault P, Atique A, Carrier F, Cheng M, Codan C . Characteristics and outcomes of patients with COVID-19 admitted to hospital and intensive care in the first phase of the pandemic in Canada: a national cohort study. CMAJ Open. 2021; 9(1):E181-E188. PMC: 8034299. DOI: 10.9778/cmajo.20200250. View

20.

Marco D, Canela J, Brey M, Soriano A, Pitart C, Herrera S . Assessing the influence of the COVID-19 pandemic on the incidence, clinical presentation, and clindamycin resistance rates of infections. IJID Reg. 2024; 11:100349. PMC: 10973571. DOI: 10.1016/j.ijregi.2024.03.004. View